Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMPLNASDAQ:KZIANASDAQ:QNRXNASDAQ:SBFM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMPLImpel Pharmaceuticals$0.27$0.02▼$4.20$956K1.17682,655 shs720,000 shsKZIANovogen$6.77-26.0%$4.73$2.86▼$79.00$9.22M2.48383,588 shs250,508 shsQNRXQuoin Pharmaceuticals$8.58-1.4%$7.60$5.01▼$54.95$5.12M1.43136,989 shs13,667 shsSBFMSunshine Biopharma$1.43-0.7%$1.43$1.17▼$9.36$6.56M1.41594,154 shs27,605 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMPLImpel Pharmaceuticals0.00%0.00%0.00%0.00%0.00%KZIANovogen-26.01%-25.19%+89.11%+36.75%-49.40%QNRXQuoin Pharmaceuticals-1.38%+1.90%-3.60%-12.82%-59.97%SBFMSunshine Biopharma-0.69%-11.18%-0.69%-32.86%+346.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMPLImpel PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKZIANovogen3.9642 of 5 stars3.55.00.00.03.90.00.0QNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASBFMSunshine Biopharma2.5027 of 5 stars3.55.00.00.00.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMPLImpel Pharmaceuticals 0.00N/AN/AN/AKZIANovogen 3.00Buy$57.50749.34% UpsideQNRXQuoin Pharmaceuticals 0.00N/AN/AN/ASBFMSunshine Biopharma 3.00Buy$15.00948.95% UpsideCurrent Analyst Ratings BreakdownLatest IMPL, KZIA, SBFM, and QNRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025KZIANovogenMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMPLImpel Pharmaceuticals$20.99M0.00N/AN/A($1.86) per share0.00KZIANovogen$1.51M4.53N/AN/A($9.87) per share-0.69QNRXQuoin PharmaceuticalsN/AN/AN/AN/A$35.47 per shareN/ASBFMSunshine Biopharma$34.87M0.19N/AN/A$9.10 per share0.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMPLImpel Pharmaceuticals-$106.31M-$3.13N/AN/AN/A-353.93%N/A-127.43%N/AKZIANovogen-$17.56MN/A0.00∞N/AN/AN/AN/AN/AQNRXQuoin Pharmaceuticals-$8.96M-$48.81N/AN/AN/AN/A-148.97%-77.23%8/14/2025 (Estimated)SBFMSunshine Biopharma-$5.13M-$150.88N/A∞N/A-13.88%-21.25%-16.89%8/15/2025 (Estimated)Latest IMPL, KZIA, SBFM, and QNRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SBFMSunshine BiopharmaN/A-$0.44N/A-$0.44N/A$8.90 million5/13/2025Q1 2025QNRXQuoin Pharmaceuticals-$3.85-$6.50-$2.65-$6.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMPLImpel PharmaceuticalsN/AN/AN/AN/AN/AKZIANovogenN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ASBFMSunshine BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMPLImpel PharmaceuticalsN/A0.190.13KZIANovogenN/A0.21N/AQNRXQuoin PharmaceuticalsN/A2.572.57SBFMSunshine BiopharmaN/A4.252.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMPLImpel Pharmaceuticals73.88%KZIANovogen30.89%QNRXQuoin Pharmaceuticals8.63%SBFMSunshine Biopharma41.98%Insider OwnershipCompanyInsider OwnershipIMPLImpel Pharmaceuticals6.20%KZIANovogen1.00%QNRXQuoin Pharmaceuticals3.70%SBFMSunshine Biopharma0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMPLImpel Pharmaceuticals16023.90 million22.42 millionNot OptionableKZIANovogen121.01 million997,000OptionableQNRXQuoin Pharmaceuticals4590,000566,000Not OptionableSBFMSunshine Biopharma34.56 million4.55 millionNot OptionableIMPL, KZIA, SBFM, and QNRX HeadlinesRecent News About These CompaniesSunshine Biopharma (NASDAQ:SBFM) Trading Down 0.7% - Here's What HappenedJune 24 at 3:05 AM | americanbankingnews.comSunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’June 11, 2025 | msn.comSunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion MarketJune 11, 2025 | accessnewswire.comSunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last YearMay 15, 2025 | accessnewswire.comSunshine Biopharma Inc.: Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion MarketMay 6, 2025 | finanznachrichten.deSunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion MarketMay 6, 2025 | accessnewswire.comSunshine Biopharma launches Everolimus in CanadaApril 22, 2025 | markets.businessinsider.comSunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 BillionApril 21, 2025 | accessnewswire.comSunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct OfferingApril 3, 2025 | accessnewswire.comThis Pharma Stock Is Gaining Major Steam Ahead Of Opening BellApril 2, 2025 | msn.comSunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq RulesApril 2, 2025 | accessnewswire.comSunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer DrugApril 2, 2025 | benzinga.comSunshine Biopharma Announces Positive Results of mRNA Therapy for CancerApril 2, 2025 | finance.yahoo.comSunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last YearApril 1, 2025 | accessnewswire.comSunshine Biopharma signs agreement for rights to market two generic antibioticsMarch 24, 2025 | msn.comSunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in CanadaMarch 24, 2025 | accessnewswire.comSunshine Biopharma Inc.: Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million MarketMarch 10, 2025 | finanznachrichten.deSunshine Biopharma’s Nora Pharma acquires gastrointestinal drug rightsMarch 10, 2025 | markets.businessinsider.comSunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million MarketMarch 10, 2025 | accessnewswire.comSunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODTJanuary 21, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeWorkday Stock Price Implosion: An Automatic Buy for AI InvestorsBy Thomas Hughes | May 26, 2025View Workday Stock Price Implosion: An Automatic Buy for AI InvestorsAnalysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernBy Leo Miller | June 2, 2025View Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernAre NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista?By Leo Miller | June 6, 2025View Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista?IMPL, KZIA, SBFM, and QNRX Company DescriptionsImpel Pharmaceuticals NASDAQ:IMPLImpel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.Novogen NASDAQ:KZIA$6.77 -2.38 (-26.01%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$6.68 -0.09 (-1.26%) As of 06/23/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Quoin Pharmaceuticals NASDAQ:QNRX$8.58 -0.12 (-1.38%) Closing price 06/23/2025 03:52 PM EasternExtended Trading$8.61 +0.03 (+0.35%) As of 06/23/2025 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.Sunshine Biopharma NASDAQ:SBFM$1.43 -0.01 (-0.69%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$1.46 +0.04 (+2.45%) As of 06/23/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
